#Weekly digest
The Saturday roundup format.
Tirzepatide: what experts said, Q2 2026
SURMOUNT-MAINTAIN, a safety review on sarcopenia risk, and early type-1 diabetes signals from credentialed researchers this quarter.
CJC-1295 Q3 2026: what actually changed
The FDA's compounding panel voted on seven peptides in July. CJC-1295 was not one of them, and a new June review grades its evidence B and D.
TB-500 in 2026 Q2: what changed
Q2 2026 gave TB-500 an FDA compounding review date and one new thymosin beta 4 heart trial, while the injury recovery evidence stayed still.
Tesamorelin in 2026 Q2: what changed
Q2 2026 gave tesamorelin one null cognition pilot and three reviews. Its FDA label, its EU status and its trial pipeline all stayed put.
Tirzepatide in 2026 Q2: what changed
Q2 2026 brought tirzepatide maintenance data, an FDA 503B compounding proposal, and warning letters about unapproved and compounded products.
Semax in 2026 Q2: what changed
Q2 2026 gave Semax an FDA compounding review date and a public docket, while the clinical evidence base for the peptide did not move.
Retatrutide in 2026 Q2: what changed
Retatrutide closed its first Phase 3 obesity trial, published its first Phase 3 diabetes paper, and stayed unapproved in every market we cover.
Semaglutide in 2026 Q2: what changed
Semaglutide gained an oral tablet in Europe and the UK during Q2 2026, while the FDA moved to close the bulk route compounders rely on.
Ipamorelin Q3 2026: what changed
Four peer-reviewed 2026 reviews name ipamorelin in clinical framing. Regulatory status is unchanged and the evidence gap remains open.
PT-141 2026-Q3: what changed this quarter
A new meta-analysis, a commentary on male use, and Palatin obesity-combination data: three developments that moved the bremelanotide picture in Q3 2026.
Semax Q3 2026: what changed
Q3 2026 update on Semax: new preclinical papers on spinal cord injury and Alzheimer's, plus the FDA PCAC meeting that reviewed Semax for the 503A bulks list.
TB-500 Q3 2026: what changed
Q3 2026 update on TB-500: four new 2026 reviews, the Topol cancer-signal status, the FDA PCAC July meeting, and WADA prohibition unchanged.